2023
The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-Engagement
2022
Advancing data to care strategies for persons with HIV using an innovative reconciliation process
Villanueva M, Miceli J, Speers S, Nichols L, Carroll C, Jenkins H, Altice F. Advancing data to care strategies for persons with HIV using an innovative reconciliation process. PLOS ONE 2022, 17: e0267903. PMID: 35511958, PMCID: PMC9071117, DOI: 10.1371/journal.pone.0267903.Peer-Reviewed Original ResearchConceptsDisease intervention specialistsHIV care continuumCare continuumNon-randomized patientsPublic health surveillance dataOngoing HIV transmissionClinic visit dataHealth surveillance dataPublic health surveillanceHIV clinicHIV eliminationViral loadHIV transmissionCare engagementCopies/Clinic staffClinic dataYale University SchoolVisit dataHealth surveillancePWHSurveillance dataPatientsCells/Intervention specialists
2020
Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIV
2019
Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations
Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. BMC Infectious Diseases 2019, 19: 913. PMID: 31664910, PMCID: PMC6819597, DOI: 10.1186/s12879-019-4443-z.Peer-Reviewed Original ResearchConceptsViral loadART adherenceAdherence measuresSelf-reported antiretroviral therapy (ART) adherenceCriminal justice-involved populationsSelf-reported ART adherenceLogistic regressionSelf-reported health statusContinuum of HIVDetectable viral loadPlasma viral loadAIDS Research NetworkAntiretroviral therapy adherenceAssociation of adherenceHealth status levelsVisual analog scaleViral load dataMixed-effects logistic regressionMixed effects linear regressionEffects linear regressionJustice-involved populationsEffects logistic regressionVL outcomesCD4 countART dosesImpact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load
Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. Clinical Infectious Diseases 2019, 70: 867-874. PMID: 30994900, PMCID: PMC7319266, DOI: 10.1093/cid/ciz299.Peer-Reviewed Original ResearchMeSH KeywordsHIVHIV InfectionsHumansIllicit DrugsLongitudinal StudiesSubstance-Related DisordersViral LoadConceptsMethamphetamine/crystalViral suppressionViral loadIllicit opioidsIllicit drug useDrug useRelative viral loadHuman immunodeficiency virus (HIV) viral loadNumber of PLWHSubstance useHIV viral loadHuman immunodeficiency virusLongitudinal cohort studyHarm reduction interventionsCrystal useCocaine/crackHIV clinicCohort studyVL suppressionImmunodeficiency virusImpact of abstinenceClinical studiesHigher oddsDrug categoriesOpioidsThe accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal Of Viral Hepatitis 2019, 26: 329-336. PMID: 30412325, DOI: 10.1111/jvh.13037.Peer-Reviewed Original ResearchMeSH KeywordsAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesData Interpretation, StatisticalFemaleGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMalePredictive Value of TestsQuinoxalinesReproducibility of ResultsSensitivity and SpecificitySulfonamidesSustained Virologic ResponseViral LoadConceptsBaseline viral loadResistance-associated substitutionsNS5A resistance-associated substitutionsEBR/GZRElbasvir/grazoprevirGenotype 1a infectionViral loadNegative predictive valuePositive predictive valuePredictive valueBaseline NS5a resistance-associated substitutionsHepatitis C virus infectionPoor negative predictive valueEuropean treatment guidelinesC virus infectionSustained virologic responseHigh positive predictive valueEBR 50GT1a infectionVirologic failureVirologic responseTreatment guidelinesTreatment outcomesVirus infectionStratification factors
2018
Factors Associated with HIV Viral Suppression Among Transgender Women in Lima, Peru
Rich KM, Wickersham JA, Huamaní J, Kiani SN, Cabello R, Elish P, Arce J, Pizzicato LN, Soria J, Sanchez J, Altice FL. Factors Associated with HIV Viral Suppression Among Transgender Women in Lima, Peru. LGBT Health 2018, 5: 477-483. PMID: 30874476, PMCID: PMC6306649, DOI: 10.1089/lgbt.2017.0186.Peer-Reviewed Original ResearchConceptsHIV-positive transgender womenViral suppressionTransgender womenUse disordersViral suppression ratesHIV viral suppressionMultivariable logistic regressionAdverse health outcomesSubstance use disordersAlcohol use disorderSevere drug useUse of drugsHIV statusSubstance disordersHigh burdenHigh prevalenceCondomless sexPsychiatric disordersAnal sexFactors AssociatedHealth outcomesDrug useHIV researchLogistic regressionLast partnerExtended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionCorrelates of viral suppression among HIV-infected men who have sex with men and transgender women in Lima, Peru
Rich KM, Huamaní J, Kiani SN, Cabello R, Elish P, Arce J, Pizzicato LN, Soria J, Wickersham JA, Sanchez J, Altice FL. Correlates of viral suppression among HIV-infected men who have sex with men and transgender women in Lima, Peru. AIDS Care 2018, 30: 1341-1350. PMID: 29843518, PMCID: PMC8236114, DOI: 10.1080/09540121.2018.1476657.Peer-Reviewed Original ResearchMeSH KeywordsAdultFemaleHIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedPeruTransgender PersonsViral LoadExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2017
Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study
Loeliger KB, Altice FL, Desai MM, Ciarleglio MM, Gallagher C, Meyer JP. Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. The Lancet HIV 2017, 5: e96-e106. PMID: 29191440, PMCID: PMC5807129, DOI: 10.1016/s2352-3018(17)30209-6.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesHIV careViral suppressionTreatment outcomesPoor HIV treatment outcomesMore medical comorbiditiesPost-release linkagePredictors of linkageRetrospective cohort studyDetectable viral loadCase management servicesCase management dataTransitional case managementHealth care goalsAntiretroviral therapyMedical comorbiditiesCohort studyRetrospective cohortDays of releaseViral loadPharmacy databasePsychiatric comorbidityUS National InstitutesCase management needsHispanic ethnicity
2016
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States
Sweet DE, Altice FL, Cohen CJ, Vandewalle B. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLOS ONE 2016, 11: e0147821. PMID: 26808503, PMCID: PMC4725959, DOI: 10.1371/journal.pone.0147821.Peer-Reviewed Original ResearchConceptsSingle-tablet regimensSubstantial price reductionsTenofovir disoproxil fumarate/emtricitabineCost-effectiveness thresholdIncremental cost-effectiveness ratioGeneric medicationsDaily single-tablet regimensDisoproxil fumarate/emtricitabineCost-effectiveness ratioElvitegravir/cobicistatCombination antiretroviral therapyHIV-1 patientsSingle-tablet regimenHigher inpatient costsHIV-1 infectionIncremental lifetime costPrice reductionEconomic outcomesMicrosimulation modelSuch policiesGeneric lamivudineTablet regimensAntiretroviral therapyU.S. settingsComplex regimens
2015
Effect of Ebola progression on transmission and control in Liberia.
Yamin D, Gertler S, Ndeffo-Mbah ML, Skrip LA, Fallah M, Nyenswah TG, Altice FL, Galvani AP. Effect of Ebola progression on transmission and control in Liberia. Annals Of Internal Medicine 2015, 162: 11-7. PMID: 25347321, PMCID: PMC4402942, DOI: 10.7326/m14-2255.Peer-Reviewed Original ResearchConceptsCase fatalityDisease progressionContacts of patientsEntire infectious periodDeadliest Ebola epidemicSingle infected caseStochastic transmission modelSymptom onsetIll patientsViral loadClinical dataSymptomatic phaseHigh riskSecondary infectionLiberian MinistryInfected individualsNonsurvivorsTargeted interventionsMontserrado CountyInfected casesEbola incidenceEbola epidemicInfectious periodNational InstituteProgression
2014
Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2012
A Systematic Review of Antiretroviral Adherence Interventions for HIV-Infected People Who Use Drugs
Binford MC, Kahana SY, Altice FL. A Systematic Review of Antiretroviral Adherence Interventions for HIV-Infected People Who Use Drugs. Current HIV/AIDS Reports 2012, 9: 287-312. PMID: 22936463, PMCID: PMC3495269, DOI: 10.1007/s11904-012-0134-8.Peer-Reviewed Original ResearchConceptsMedication-assisted therapyCART adherenceVirologic outcomesSystematic reviewCombination antiretroviral therapy (cART) adherenceAntiretroviral Adherence InterventionPost-intervention adherenceHIV treatment outcomesHIV clinical careAntiretroviral therapy adherenceNurse-delivered interventionShort-term adherenceCognitive behavioral therapyLong-term improvementPeer-driven interventionVirologic benefitAntiretroviral therapyDevelopment of interventionsIntervention cessationAdherence interventionsProspective studyTherapy adherenceEligible studiesTreatment outcomesClinical careDeveloping a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication
Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication. The American Journal Of Drug And Alcohol Abuse 2012, 38: 206-212. PMID: 22242700, PMCID: PMC5573865, DOI: 10.3109/00952990.2011.643975.Peer-Reviewed Original ResearchConceptsSustained virologic responseEarly virologic responseMethadone maintenance treatmentHepatitis C treatmentSelf-administered therapyHepatitis C virusHCV treatmentVirologic responseAdherence supportWeek 12HCV treatment adherenceOpioid-dependent patientsBlood-borne infectionsMethadone-maintained patientsCompletion of treatmentCase-control studyMethadone maintenance clinicsMethadone maintenance programMental illness comorbidityConcurrent substance useC treatmentObserved therapyHCV genotypesHIV statusIllness comorbidity
2011
Medication Persistence of HIV-infected Drug Users on Directly Administered Antiretroviral Therapy
Ing EC, Bae JW, Maru DS, Altice FL. Medication Persistence of HIV-infected Drug Users on Directly Administered Antiretroviral Therapy. AIDS And Behavior 2011, 17: 113-121. PMID: 22105340, DOI: 10.1007/s10461-011-0082-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBehavior, AddictiveCD4 Lymphocyte CountConnecticutDirectly Observed TherapyDrug UsersFemaleHIV InfectionsHumansInterviews as TopicKaplan-Meier EstimateMaleMedication AdherenceProportional Hazards ModelsRandomized Controlled Trials as TopicRNA, ViralSeverity of Illness IndexSubstance Abuse, IntravenousTreatment OutcomeViral LoadConceptsDrug usersAntiretroviral therapyPatterns of medicationInjection drug useMedication-taking behaviorHigher depressive symptomsVirological outcomesMedication persistenceRegimen changeMore episodesDepressive symptomsHigher addiction severityDrug useSignificant associationConsecutive daysHIVAddiction severityMedicationsMEMS dataTherapyDaysEpisodesParticipantsRegimensDAARTRationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes
Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2011, 33: 436-444. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesSelf-administered therapyAntiretroviral therapyTreatment outcomesViral loadEvidence-based adherence interventionsPoor HIV treatment outcomesGenotypic resistance testingMedication-assisted treatmentDSM-IV criteriaAlcohol use disorderCase management servicesViral suppressionPrimary outcomeOpioid dependenceAdherence interventionsCD4 testingIntervention periodStudy groupEligibility criteriaUse disordersIntervention monthDrug usersAdverse HIVHIVComputer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project
Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, Friedland G, for the LifeWindows Team. Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project. AIDS And Behavior 2011, 15: 1635. PMID: 21452051, DOI: 10.1007/s10461-011-9926-x.Peer-Reviewed Original ResearchConceptsHIV clinical care settingsAdherence support interventionsClinical care sitesClinical care settingsHIV careCare visitsAntiretroviral adherenceControl armCare settingsCare sitesProtocol interventionTreat sampleProtocol sampleSupport interventionsComputer-based interventionsIntervention impactControl participantsInterventionAdherenceHIVPatientsCareHigh levelsClinicARVMedication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research
Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011, 25: 279-290. PMID: 21239892, DOI: 10.1097/qad.0b013e328340feb0.Peer-Reviewed Original ResearchConceptsClinical outcomesPrescribed therapyFuture clinical careSuboptimal persistenceVirological failureAntiretroviral resistanceMedication persistenceHIV infectionMedication treatmentHIV treatmentCertain regimensClinical consequencesClinical carePatient behaviorPatientsContinuous treatmentUnderrecognized aspectsTherapyAdherenceHIVTreatmentShort durationCurrent literatureDurationIntervention